文献速递炎症性肠病消化内镜

全结肠内镜与组织学评估预测溃疡性结肠炎临床缓解期复发

Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission.
PubMed 文献 · Aliment Pharmacol Ther · 2021-03-01

研究纳入325例临床和生化缓解的溃疡性结肠炎患者,系统评估5个结肠段的内镜(UCEIS三种模式)和组织学(Geboes评分),前瞻性随访1年。结果显示全结肠UCEIS预测价值最高(AUC 0.852),内镜活动(全结肠UCEIS>3)和组织学活动(Geboes>3.0)为复发的独立危险因素,联合评估可提高复发避免的敏感性和特异性。

要点

  • 全结肠UCEIS评估对1年内临床复发的预测价值优于原法和最严重部位法。
  • 全结肠UCEIS>3和Geboes>3.0是复发的独立危险因素(HR分别为3.96和3.48)。
  • 联合全结肠UCEIS≤3和Geboes≤3.0预测1年无复发的敏感性92.0%、特异性97.0%。

核心结论

  • 完整结肠镜评估疾病缓解具有临床意义,联合全结肠内镜和组织学评估可恰当评价黏膜愈合。

研究设计与样本

  • 前瞻性队列研究,纳入2018年4月至2019年3月连续325例临床和生化缓解的溃疡性结肠炎患者。
  • 系统评估5个结肠段的内镜(UCEIS三种模式:original、worst affected、pancolonic)和组织学(Geboes评分),随访1年,主要终点为临床复发。

主要发现

  • 结肠镜后1年内18.2%的患者发生临床复发。
  • ROC曲线分析显示original、worst affected和pancolonic组AUC分别为0.755、0.817和0.852,pancolonic UCEIS预测价值最高。
  • 以pancolonic UCEIS cut-off值为3,Kaplan-Meier分析显示内镜活动患者无复发率显著低于内镜缓解患者(P < 0.01)。
  • 多因素分析显示内镜活动(pancolonic UCEIS >3)和组织学活动(Geboes >3.0)是复发的独立危险因素(HR:3.96和3.48)。
  • 联合pancolonic UCEIS ≤3和Geboes评分≤3.0预测1年复发避免的敏感性为92.0%,特异性为97.0%。

关键数值与推荐

  • pancolonic UCEIS cut-off值为3。
  • Geboes评分cut-off值为3.0。
  • 联合pancolonic UCEIS ≤3和Geboes评分≤3.0预测1年复发避免的敏感性92.0%、特异性97.0%。

临床怎么用

  • 对临床缓解的溃疡性结肠炎患者,建议行完整结肠镜检查并采用全结肠UCEIS评分系统评估。
  • 结合全结肠内镜(UCEIS≤3)和组织学(Geboes≤3.0)评估黏膜愈合,以更准确预测复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mucosal healing is an important treatment target in patients with ulcerative colitis. AIMS: To explore the optimal colonoscopic strategy to determine the risk for clinical relapse in patients with ulcerative colitis. METHODS: We enrolled 325 consecutive patients with ulcerative colitis in clinical and biochemical remission from April 2018 to March 2019. Five colonic segments were endoscopically and histologically assessed systematically. For endoscopic evaluation, we used three different modes of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS): "original," "worst affected," and "pancolonic." The Geboes score was used for histological evaluation. We prospectively followed up the patients and defined clinical relapse as the primary endpoint. RESULTS: Within 1 year after colonoscopy, 18.2% of patients experienced a clinical relapse. Receiver operating characteristic curve analysis showed areas under the curve of 0.755, 0.817, and 0.852 for the "original," "worst affected," and "pancolonic" groups, respectively; hence, pancolonic UCEIS obtained the highest predictive value. Using the pancolonic UCEIS cutoff value of 3, Kaplan-Meier curve analysis showed that patients with endoscopic activity had a significantly lower relapse-free rate than those with endoscopic remission (P < 0.01). Multivariate analysis demonstrated endoscopic (pancolonic UCEIS >3) and histological (Geboes >3.0) activities as independent risks for relapse (HR: 3.96 and 3.48, respectively). Combining pancolonic UCEIS ≤3 and Geboes score ≤3.0 to provide 1-year relapse avoidance was 92.0% sensitive and 97.0% specific. CONCLUSION: Evaluating disease remission by complete colonoscopy is relevant, and the combination of pancolonic endoscopic and histological evaluations may appropriately evaluate mucosal healing.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kaneshiro M, Takenaka K, Suzuki K, et al. Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission. Aliment Pharmacol Ther. 2021. PMID: 33645736. doi:10.1111/apt.16310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。